Tier 2 — strong
Comparative Efficacy and Pharmacokinetic Parameters of Micronized Creatine Monohydrate (KleanCREATINE™) in Active Men: A Randomized, Controlled Clinical Study
Cureus
2026
18(2):e103091
Bibliography
- PubMed
- PMID 41809290
- PubMed Central
- PMC12968080
- Funding
- All trial-related expenses and investigational-product expenses were borne by Lasons India Pvt. Ltd.
- Competing interests
- Pravin Aggarwal reported employment with Lasons India Pvt. Ltd., which funded the trial and investigational product. The other author declared no conflict of interest.
Study snapshot
| Design | Two-phase randomized controlled clinical study: open-label crossover pharmacokinetics plus double-blind parallel efficacy phase |
|---|---|
| Model | Human evidence synthesis or trial |
| Sample | 10 active men in the crossover pharmacokinetic phase; 52 active men in the eight-week parallel efficacy phase |
| Intervention | 3 g/day KleanCREATINE micronized creatine monohydrate versus a marketed creatine monohydrate |
| Duration | Single-dose pharmacokinetic phase plus 8-week efficacy phase |
| Endpoints | Plasma creatine pharmacokinetics; Relative bioavailability; Strength; Muscle endurance; Body composition; Perceived exertion; Safety |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified

